Fordel StudiosConverge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz
What Happened
AI drug discovery startup Converge Bio raised $25 million in a Series A led by Bessemer Venture Partners, with additional backing from executives at Meta, OpenAI, and Wiz.
Our Take
Drug discovery AI is real now. This isn't vaporware. Bessemer knows biotech, and having OpenAI/Meta execs on the cap table means they've got smart people who've shipped at scale.
$25M is real money for drug discovery—gets you compute, datasets, maybe a first trial. The bet's that AI can compress the screening phase from months to weeks.
Caveat: drug discovery success lives in years, not quarters. Might work, might not. But serious investors actually building teams (not just advising) is bullish.
What To Do
If you're in biotech infrastructure, Converge's probably hiring—watch their careers page.
Cited By
React